Immune Therapeutics, Inc. is a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a well-defined path to market. By utilizing a biotech portfolio hub-and-spoke engine, we plan to advance focused and efficient small-scale biotechnology and pharmaceutical programs through subsidiaries, investment vehicles or partnerships, and deploy products from those programs in markets both in the U.S. and internationally for initial commercialization.
Company profile
Ticker
BTAX
Exchange
Website
CEO
Noreen Griffin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Immune Therapeutics, Inc., TNI BIOTECH, INC.
SEC CIK
Corporate docs
Subsidiaries
TNI BioTech International, Ltd. • TNI BioTech, LTD • Airmed Biopharma Limited • Airmed Holdings Limited • Cytocom, Inc., USA. Incorporated ...
BTAX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
2 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
24 Oct 23
8-K
Biostax Corp Announces the Passing of Esteemed Director, Henry Louis Salomonsky
14 Sep 23
8-K
Departure of Directors or Certain Officers
13 Sep 23
10-Q
2023 Q2
Quarterly report
18 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
Latest ownership filings
4
Glen A Farmer
22 Feb 23
SC 13D
Salomonsky Henry Louis
15 Dec 22
3
Initial statement of insider ownership
15 Dec 22
3
Henry Louis Salomonsky
15 Dec 22
3
Glen A Farmer
15 Dec 22
3
Kelly O'Brien Wilson
15 Dec 22
3
FAMILY TRUST DTD ROGOFF
7 Jun 21
SC 13D
Griffin Noreen
7 Jun 21
3
Joel Yanowitz
7 Jun 21
3
George Sasko
7 Jun 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.53 k | 4.53 k | 4.53 k | 4.53 k | 4.53 k | 4.53 k |
Cash burn (monthly) | 4.30 k | 15.08 k | 117.44 k | 121.71 k | (no burn) | 12.78 k |
Cash used (since last report) | 29.75 k | 104.35 k | 812.87 k | 842.41 k | n/a | 88.49 k |
Cash remaining | -25.22 k | -99.82 k | -808.33 k | -837.88 k | n/a | -83.96 k |
Runway (months of cash) | -5.9 | -6.6 | -6.9 | -6.9 | n/a | -6.6 |
Institutional ownership, Q3 2022
14.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 12.20 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Henry Louis Salomonsky | 12.17 mm | $0.00 |
Noreen Griffin | 28.27 k | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Feb 23 | Glen A Farmer | Common Stock | Buy | Acquire P | No | No | 0.045 | 409,000 | 18.41 k | 409,000 |